ArticleFrontiers in immunology2026

Efficacy and safety of efgartigimod as an add-on therapy in patients with NMOSD and MOGAD at the acute attack phase.

Weifan Yin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.